Abingworth’s Immune Design Corp. IMDZ Stock Holding History

Abingworth’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-352,300	Closed	-$458K	–	19
2018 Q4	$458K	Hold	352,300	–	–	0.42%	15
2018 Q3	$1.2M	Hold	352,300	–	–	0.71%	15
2018 Q2	$1.62M	Hold	352,300	–	–	0.93%	15
2018 Q1	$1.15M	Hold	352,300	–	–	0.71%	15
2017 Q4	$1.37M	Hold	352,300	–	–	1%	15
2017 Q3	$3.65M	Hold	352,300	–	–	2.52%	8
2017 Q2	$3.4M	Hold	352,300	–	–	2.71%	6
2017 Q1	$2.38M	Buy	352,300 +155,000	+79%	+$896K	1.77%	11
2016 Q4	$1.07M	Hold	197,300	–	–	0.9%	14
2016 Q3	$1.49M	Hold	197,300	–	–	1.43%	16
2016 Q2	$1.61M	Buy	+197,300	New	+$2.46M	1.69%	15

Other funds holding IMDZ

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

SAM

Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Abingworth's IMDZ Position: Q1 2019 in Review

Abingworth sold out of Immune Design Corp. (IMDZ) in Q1 2019, closing a stake of 352,300 shares — an estimated $458K sold.

Abingworth first reported a position in IMDZ in Q2 2016 and held it in 11 quarters. The position peaked at $3.65M in Q3 2017. 68 funds tracked by Wall St. Rank hold IMDZ as of Q1 2019.

Abingworth reported no remaining Immune Design Corp. position as of Q1 2019 after selling out during the quarter.
Abingworth sold 352,300 Immune Design Corp. shares in Q1 2019, an estimated $458K.
Abingworth first reported a position in Immune Design Corp. in Q2 2016 and held it in 11 quarters.
Abingworth's Immune Design Corp. position peaked at $3.65M in Q3 2017.
68 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2019.

Based on Abingworth's 13F filing for Q1 2019, filed 15 May 2019.